DrugDashboards

dasatinib

dasatinib · DASATINIB 140 mg/1 · Tablet · Oral · Zydus Lifesciences Limited

NDC 70771-1906-03 · 30 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 70709-0156-14) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$634.41per unit
middle half $609.58–$634.41 · 1,232 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $634.41
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
22%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 99%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 1 quarter since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.0%chance of a new FDA shortage posting for dasatinib (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $9,151.34 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA218719
TE code
AB
Approval date
Mar 3, 2025
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of dasatinib (Tablet)

LabelerStrengthFirst seenLast seen
Aurobindo Pharma LimitedDASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDASATINIB 80 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDASATINIB 70 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedDASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals LtdDASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals LtdDASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals LtdDASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals LtdDASATINIB 80 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals LtdDASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals LtdDASATINIB 70 mg/1Jul 15, 2026Sep 2, 2026
E.R. Squibb & Sons, L.L.C.DASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
E.R. Squibb & Sons, L.L.C.DASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026
E.R. Squibb & Sons, L.L.C.DASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
E.R. Squibb & Sons, L.L.C.DASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
E.R. Squibb & Sons, L.L.C.DASATINIB 70 mg/1Jul 15, 2026Sep 2, 2026
E.R. Squibb & Sons, L.L.C.DASATINIB 80 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.DASATINIB 70 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.DASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.DASATINIB 80 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.DASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.DASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.DASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026
Patheon, Inc.DASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
Patheon, Inc.DASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026
Patheon, Inc.DASATINIB 70 mg/1Jul 15, 2026Sep 2, 2026
Patheon, Inc.DASATINIB 80 mg/1Jul 15, 2026Sep 2, 2026
Patheon, Inc.DASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
Patheon, Inc.DASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesDASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesDASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesDASATINIB 70 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesDASATINIB 80 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesDASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
Prasco LaboratoriesDASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedDASATINIB 140 mg/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedDASATINIB 20 mg/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedDASATINIB 50 mg/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedDASATINIB 100 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "dasatinib — NDC 70771-1906-03," retrieved September 3, 2026, https://drugdashboards.com/drug/70771190603.

Free to cite with attribution — see how the data is put together.